|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 1999~2006年急性冠脉综合征患者死亡及心力衰竭发生率降低显示文摘背景:有关药物和介入治疗对ST段抬高型和非ST段抬高型急性冠脉综合征(non—ST-segment elevation acute coronary syndrome,NSTE ACS)患者的作用,随机试验已经提供了足够的证据,但是是否已经转化为相应的临床变化还不清楚。
目的:确定ST段抬高型心肌梗死(ST-segment elevation myocardial infarction,STEMI)和NSTE ACS患者的院内治疗改变是否伴随临床结果的改善。
设计、地点及患者:全球急性冠脉事件注册研究(Global Registry of Acute Coronary Events,GRACE)是一项多国家队列研究。自1999年7月1日至2006年12月31日,该研究共入选并随访了来自14个国家、113家医院的44372例ACS患者。
主要观测指标:当前循证药物和介入治疗应用的趋势及患者预后(死亡、充血性心力衰竭、肺水肿、心源性休克、卒中和心肌梗死)。
结果:随着研究时间的进展,相关药物的应用增加(β-受体阻滞剂、他汀类药物、血管紧张素转换酶抑制剂、行或未行经皮冠状动脉介入治疗[percutaneous coronary intervention,PCI]患者应用噻氯毗啶、糖蛋白Ⅱb/Ⅲa抑制剂和低分子肝素;P〈0.001)。STEMI患者药物再灌注治疗下降了22个百分点(95%可信区间[confidence interval,CI],-27~-17),而直接PCI增加了37个百分点(95%CI,33—41)。在NSTEMI患者中,PCI的比例显著升高了18个百分点(95%CI,15~20)。充血性心力衰竭和肺水肿在STEMI患者中降低了9个百分点(95%CI,-12~-6),在NSTEACS患者中降低了6.9个百分点(95%CI,-8.4~-4.7)。STEMI患者的院内死亡率降低了18个百分点(95%CI,-5.3~-1.9),心源性休克降低了24个百分点(95%CI,-4.3~-0.5)。校正了危险评分后,NSTEACS患者的院内死亡率降低了0.7个百分点(95%CI,-1.7~0.3);STEMI患者6个月随访时卒中发生率降低了0.8个百分点(95%CI,-1.7~0.1),心肌梗死发生率降低了2.8个百分点(95%CI,-6.4~0.9)。NSTEACS患者6个月死亡率降低了1.6个百分点(95%CI,-3.0~-0.1),卒中发生率降低了0.7个百分点(95%CI,-1.4~0.1)。
结论:在本项多国家观察性研究中,ACS患者治疗的改善与6个月新发心力衰竭、死亡率、卒中和心肌梗死发生率显著降低相关。 | Keith A. A. Fox Philippe Gabriel Steg Kim A. Eagle Shaun G. Goodman Frederick A. Anderson Christopher B. Granger Marcus D. Flather Andrzej Budaj Ann Quill Joel M. Gore 康俊萍(译) 马长生(校) | 2007 | 美国医学会杂志(中文版)2007，26，6： | 6 |
| 2 | The microsatellite polymorphism of heme oxygenase-1 is associated with baseline plasma IL-6 level but not with restenosis after coronary in-stenting显示文摘Background Vascular smooth muscle cells (VSMCs) can express heme-oxygenase (HO), a rate-limiting enzyme in the degradation of heme to bilirubin, ferritin and carbon monoxide (CO). VSMC-derived CO can suppress VSMC proliferation and may serve as an antiproliferation factor. The promoter region of HO-1 shows a polymorphism with different (GT)_n repeats that has been reported to differently induce gene expression. The objective of this study was to examine the effect of this variation on the occurrence of restenosis after in-stent treatment in patients with coronary artery disease. Methods Candidates who underwent coronary stent implantation were genotyped for the HO-1 promoter polymorphism using polymerase chain reaction (PCR) and automated DNA capillary sequencer. Serum levels of IL-6 and C-reactive protein (CRP) were obtained at baseline, 24 hours and 48 hours after stenting. The primary end point for the study was angiographic evidence of in-stent restenosis at 6 months. All parameters for evaluation of restenosis were analysed by quantitatve computer-assisted angiographic analysis (QCA). Results One hundred and eighty-seven patients who underwent coronary stent implantation were studied of whom 27.8% showed ≥50% restenosis after 6 months. The distribution of (GT)_n repeats of all patients in the promoter region of HO-1 genotype ranged from 22 to 42, with (GT)_ 25 and (GT)_ 32 being the two most common alleles. The allelic repeats were divided into the short class (S) with 29 (GT)_n, the middle class (M) with 30-37 (GT)_n and the long class (L) with 38 (GT)_n. There was no significant difference in the restenosis between the genotype groups or between post operation levels of inflammation markers, but carriers of the S allele (n=120) had 33.3% lower baseline IL-6 compared with non-S carriers (n=67, P=0.0008). Conclusions Although no association was observed between the HO-1 promoter polymorphism aod coronary in-stent restenosis following the stent procedure, the association with plasma IL-6 levels suggests that HO-1 S allele might protect from the atherosclerotic inflammatory process. | LI Ping Mohamed A. Elrayess Abuzeid H. Gomma Jutta Palmen Emma Hawe Kim M. Fox Steve E. Humphries | 2005 | Chinese Medical Journal2005，，18： | 6 |
| 3 | 心率作为冠心病与左室收缩障碍患者的预后危险因素(BEAUTIFUL):一项随机、对照试验的一个亚组分析显示文摘背景BEAUTIFUL研究对降心率药物伊伐布雷定的发病率与病死率收益进行了评估。BEAUTIFUL试验中的安慰剂组是由稳定型冠心病与左室收缩功能障碍的大型患者队列组成。我们对该安慰剂组进行了亚组分析,旨在检验这样一种假设,即基线静息心率升高是心血管疾病发病与死亡的标志。
方法采用Cox比例风险模型,对心率≥70次/min患者(2693例)以及〈70次/min患者(2745例)进行对比,分析基线静息心率与心血管结局之间的关系。将心率作为一个连续变量,并采用更为精细的心率分类进行其他分析。
结果在对基线特征进行校正后,心率≥70次/min患者的心血管疾病死亡(34%,P=0.0041)、心力衰竭入院(53%,P=0.0001)、心肌梗死入院(46%,P=0.0066)及冠状动脉血运重建(38%,P=0.037)风险升高。心率每升高5次/min,患者的心血管疾病死亡(8%,P=0.0005)、心力衰竭入院(16%.P〈0.0001)、心肌梗死入院(7%,P=0.052)及冠状动脉血运重建(8%,P=0.034)风险亦升高。对心率精细分组的分析表明,心率〉70次/min患者的病死率与心力衰竭发生率持续升高,但这种相关性在冠状动脉结局方面并不显著。对于心力衰竭结局而言,静息心率对早期事件的预测价值较晚期事件的预测价值更强。
结论在冠心病和左室收缩功能障碍的患者中,心率升高(≥70次/min)意味着心血管疾病结局风险升高,同时对心力衰竭相关性结局与冠状动脉事件相关性结局有着不同的影响。 | Kim Fox Ian Ford P Gabriel Steg Michal Tendera Michele Robertson Roberto Ferrari 罗亮(译) | 2008 | 世界临床医学2008，2，6： | 5 |
| 4 | Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials显示文摘 | Gilles R Dagenais Janice Pogue Kim Fox Marteen L Simoons Salim Yusuf | 2006 | The Lancet2006，，9535： | 2 |
| 5 | Activity and safety of crizotinib in patients with ALK -positive non-small-cell lung cancer: updated results from a phase 1 study显示文摘 | D Ross Camidge Yung-Jue Bang Eunice L Kwak A John Iafrate Marileila Varella-Garcia Stephen B Fox Gregory J Riely Benjamin Solomon Sai-Hong I Ou Dong-Wan Kim Ravi Salgia Panagiotis Fidias Jeffrey A Engelman Leena Gandhi Pasi A J?nne Daniel B Costa Geoffrey | 2012 | Lancet Oncology2012，，10： | 1 |
| 6 | Hypertension,cardiac hypertrophy,and sudden death in mice lacking natriuretic peptide receptor A显示文摘 | Oliver PM Fox JE Kim HS | 1997 | Proc Natl Acad Sci USA1997，94，14： | 1 |
| 7 | Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials显示文摘 | Gilles R Dagenais Janice Pogue Kim Fox Marteen L Simoons Salim Yusuf | 2006 | The Lancet . 2006 (9535)2006，，9535： | 1 |
| 8 | Mitochondrial DNA polymerase editing mutation,POLGD257A,reduces the diabetic phenotype of Akita male mice by suppressing appetite显示文摘 | Fox R Kim HS Reddick RL | 2011 | PNAS2011，108，21： | 1 |
| 9 | 943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial显示文摘 | B.G. Feagan P.J. Rutgeerts B.E. Sands J. Colombel W.J. Sandborn J. Colombel S.B. Hanauer G.A. Van Assche J. Axler H. Kim S. Danese I. Fox C. Milch S. Sankoh T. Wyant J. Xu A. Parikh | 2012 | Gastroenterology2012，，： | 1 |
| 10 | Activity and safety of crizotinib in patients with ALK -positive non-small-cell lung cancer: updated results from a phase 1 study显示文摘 | D Ross Camidge Yung-Jue Bang Eunice L Kwak A John Iafrate Marileila Varella-Garcia Stephen B Fox Gregory J Riely Benjamin Solomon Sai-Hong I Ou Dong-Wan Kim Ravi Salgia Panagiotis Fidias Jeffrey A Engelman Leena Gandhi Pasi A J?nne Daniel B Costa Geoffrey | 2012 | Lancet Oncology2012，，10： | 1 |
| 11 | Hypertension, cardiac hyoertrophy,and sudden death in mice lacking natriuretic peptide receptou A显示文摘 | Oliver PM Fox JE Kim R | 1997 | Proc Natl Acad Sci U S A1997，94，14： | 1 |
| 12 | Hypertension, cardiac hypertrophy and sudden death in mice lacking natriuretic peptide receptor A 显示文摘 | Oliver P Fox J Kim R | 1997 | Proc Natl Acad Sci USA1997，94，14： | 1 |
| 13 | Activity and safety of crizotinib in patients with ALK -positive non-small-cell lung cancer: updated results from a phase 1 study显示文摘 | D Ross Camidge Yung-Jue Bang Eunice L Kwak A John Iafrate Marileila Varella-Garcia Stephen B Fox Gregory J Riely Benjamin Solomon Sai-Hong I Ou Dong-Wan Kim Ravi Salgia Panagiotis Fidias Jeffrey A Engelman Leena Gandhi Pasi A J?nne Daniel B Costa Geoffrey | 2012 | Lancet Oncology2012，，10： | 1 |
| 14 | Antianginal and Antiischemic Effects of Ivabradine, an If Inhibitor, in Stable Angina: A Randomized, Double-Blind, Multicentered, Placebo-Controlled Trial显示文摘 | Jeffrey S. Borer Kim Fox Patrice Jaillon Guy Lerebours | 2003 | Circulation: Journal of the American Heart Association2003，，6： | 1 |
| 15 | Hypertension,cardiac hypertrophy,and sudden death in mice lacking natriuretic peptide receptor A显示文摘 | Oliver PM Fox JE Kim R | 1997 | Proc Natl Acad Sci U S A1997，94，14： | 1 |
| 16 | Yeast, a model organism for iron and copper metabolism studies显示文摘 | Jeane De Freitas Henri Wintz J Hyoun Kim Helen Poynton Tama Fox Chris Vulpe | 2003 | BioMetals2003，，1： | 1 |
| 17 | Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A显示文摘 | Oliver PM Fox JE Kim R | 1997 | Proc Nail Acad Sci USA1997，94，14： | 1 |
| 18 | Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A显示文摘 | Oliver PM Fox JE Kim R | 1997 | Proc Natl Acad Sci U S A1997，94，14： | 1 |
| 19 | NF- Kappa B activation and modulation in hepatic macrophages during cholestatic injury显示文摘 | Fox ES Kim JC Tracy TF | 1997 | J Surg Res1997，72，： | 1 |
| 20 | Hypertension,cardiac hypertrophy,and sudden death in mice lacking natriuretic peptide receptor A显示文摘 | Oliver PM Fox JE Kim R | 1997 | Proc Natl Acad Sci U S A1997，94，14： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员